Consider this. The S&P 500 notched an annualized return of 9.4% over a 20-year holding period. In other words, $1 invested on Jan. 1, 1995, would have grown to $6.65 by Dec. 31, 2015. If you look at just the past 10 years, the S&P's annualized return, including dividends, is still slightly over 7%. Try getting that kind of long-term performance from any investment other than equities.
Of course, a buy-and-hold strategy requires you to do exactly that -- buy and hold, during downturns as well as upturns. And that's where it goes badly wrong for some investors. While being a buy-and-hold investor feels easy in a strong market, people change their tune when losses set in. Of course, that's the nature of long-term investing. Sometimes you're surprised on the upside, and sometimes you're surprised on the downside. You take the good with the bad.
No strategy is perfect, but you can increase your gain and slash your risk further by picking the right stocks. So long as you don't participate in panic selling during market downturns, your portfolio will only emerge stronger.
And what better way to set yourself up for long-term gains than with healthcare stocks? The industry has been beaten down considerably recently, and yet the sector is filled with companies making life-saving drugs and therapies that an aging population will only demand more of.
With that in mind, here are three healthcare stocks Motley Fool contributors believe look like great choices for buy-and-hold investors.
Gilead Sciences is the leader in HIV and hepatitis C treatment, and its medicines have revolutionized patient outcomes. HIV patients now live longer, healthier lives, and for the first time, hepatitis C patients have access to drugs offering a functional cure.
As a result, Gilead Sciences' sales eclipsed $32 billion last year -- a tripling of its results in the past three years -- and while it's anyone's guess what the company will do for an encore, I think this company's track record is good enough to warrant having long-term investors give management the benefit of any doubt.
Exiting December, the company was sitting on a massive $26 billion cash stockpile that gives it tremendous flexibility to innovate organically or to acquire innovation to drive future growth. That cash also offers up plenty of sleep-at-night peace of mind.
Still not convinced? Consider that trading at an arguably bargain-bin valuation of 9 times next year's expected earnings and that its shares are paying a better-than-market 1.95% dividend yield, too.
Brian Feroldi: I think CVS Health (CVS -0.56%) qualifies as a stock to considering holding "forever" as it's in a great position to benefit from the gradual graying of America. The Pew Research Center estimates that roughly 10,000 baby boomers will turn 65 every single day for the next 19 years, which makes it a near certainty that the demand for pharmacy services will grow for years to come.
CVS Health has also made a number of savvy moves recently that should help it continue to capture an ever larger share of the U.S. pharmacy market. For example, it recently acquired all of Target's pharmacies and clinics and is in the process of rebranding all of those pharmacies under the CVS/Pharmacy name. Once that process is complete, it will offer both new and existing customers an even more convenient way to use the company's services.
Beyond that, CVS is also pushing hard to build out its network of in-store clinics -- called MinuteClinics -- that allow it to offer care for simple injuries and common colds. It currently operates more than 1,000 of these clinics, and they're a big hit with customers in offering a convenient and low-cost way to treat simple medical conditions without needing to step foot in a doctor's office or hospital.
All of these moves should help to ensure that CVS Health's financial statements continue to move in the right direction. Meanwhile, the company also has a history of taking care of its shareholders. The company pays out a dividend that yields 1.7%, and it's made a habit of regularly buying back its shares. With its stock currently trading at a forward P/E ratio of roughly 15 right now, it could be a great time for investors to add a few shares of this stock to their portfolio and simply hold on.
Cheryl Swanson: If I had to pick a stock to be wedded to "forever," it would be the most diversified healthcare company on the planet: Johnson & Johnson (JNJ 0.69%). The biggest name in the sector has notched 53 consecutive years of dividend increases and more than 30 years of adjusted operating earnings growth. That kind of track record is pretty unbeatable.
In addition, J&J's pharmaceuticals division has been knocking it out of the park. The FDA approved three new J&J drugs in the last quarter of 2015. One of the drugs approved is for multiple myeloma and one is an anti-retroviral, and these new drugs should really boost growth in the coming years. The company is already seeing strong market uptake of popular new drugs Xarelto, Invokana, Imbruvica, and Zytiga, and more new drugs are on tap. In fact, management has touted 10 new drugs and 40 line extensions for approval by 2019. The robust pipeline should more than compensate for J&J's drugs going off patent in the years ahead.
The company also has a balance sheet flush with $18.5 billion in cash, more than enough left to keep cutting bigger dividend checks for investors. And J&J's dividend is already nice-sized, sporting a 2.85% yield.
While J&J had a pretty lukewarm 2015 in terms of earnings, with EPS declining 3%, when you control for currency, earnings went up over 5%. In addition, the company has natural catalysts coming in demographic trends. North America accounts for half of J&J's sales. As the baby boomer generation enters retirement, demand will increase for the company's products -- particularly medical devices. The global market is also aging, and access to medical care is improving. These trends should benefit J&J's earnings and boost shares for many, many years.
In sum: J&J's history is amazing, and so should be its future. Over the long term, there's no reason to believe this company will stop rewarding its investors.